Compare ESPR & NXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESPR | NXP |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 731.9M | 744.2M |
| IPO Year | 2013 | 1995 |
| Metric | ESPR | NXP |
|---|---|---|
| Price | $3.13 | $14.23 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $8.75 | N/A |
| AVG Volume (30 Days) | ★ 16.9M | 150.2K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $403,135,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.81 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.31 | N/A |
| 52 Week Low | $0.76 | $13.73 |
| 52 Week High | $4.18 | $14.65 |
| Indicator | ESPR | NXP |
|---|---|---|
| Relative Strength Index (RSI) | 70.76 | 47.64 |
| Support Level | $2.37 | $13.91 |
| Resistance Level | $3.18 | $14.55 |
| Average True Range (ATR) | 0.05 | 0.15 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 96.38 | 46.88 |
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
Nuveen Select Tax Free Income Portfolio is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with preservation of capital. The fund invests a majority of its assets in municipal securities and other related investments, the income from which is exempt from regular federal income tax and federal alternative minimum tax.